March 26, 2020 / 10:36 AM / 14 days ago

BRIEF-U.S. FDA Approves Bristol Myers Squibb's Zeposia, A New Oral Treatment For Relapsing Forms Of Multiple Sclerosis

March 26 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES BRISTOL MYERS SQUIBB’S ZEPOSIA® (OZANIMOD), A NEW ORAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS

* BRISTOL-MYERS - REGULATORY DECISION FROM EMA EXPECTED IN H1 2020 FOR ZEPOSIA FOR TREATMENT OF ADULTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

* BRISTOL-MYERS SQUIBB CO - AS COUNTRY’S HEALTHCARE SYSTEM IS DEALING WITH COVID-19 PANDEMIC, CO MADE DECISION TO DELAY COMMERCIALIZATION OF ZEPOSIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below